Detection of Clostridium difficile in 40 minutes*
Xpert® Carba-R is a qualitative, on-demand real-time PCR test for the detection and differentiation of KPC, NDM, VIM, OXA-48 and IMP in 48-minutes
- Carbapenem resistance results in increased mortality in hospitalized patients and is associated with higher total hospital costs.1
- Organisms carrying integron and plasmid-encoded carbapenemase enzymes are largely responsible for the rapid spread of carbapenem resistance.2
- CDC recommends comprehensive infection control measures for patients who are colonized or infected with carbapenemase-producing organisms.3
- Current test methods lack the sensitivity, ease of use, and rapid results required to respond quickly to the threat of carbapenemase-producing organisms.
(1) Judd WR, et al. Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa–infected patients. American Journal of Infection Control. June 2016. (http://www.sciencedirect.com/science/article/pii/S0196655316303431);
Xpert® Carba-R can detect and differentiate the most prevalent carbapenemase gene families in just 48 minutes.
- Detection and differentiation of high-risk patients with Xpert Carba-R can alert clinicians and infection preventionists (IPs) rapidly to the presence of gene sequences associated with carbapenem non-susceptibility in gram-negative bacteria, including Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii.
- Rapid detection and differentiation of the blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP gene sequences from pure colonies helps clinicians optimize patient management and direct therapeutic strategy, while testing rectal and perirectal swabs helps IPs design effective infection control measures. Perirectal and rectal swabs are not intended to direct therapeutic strategy.
- Comprehensive infection control measures should be applied to patients who are colonized or infected with carbapenemase-producing organisms.3
Number of Tests: 10Catalog #: GXCARBAR-10
Gian Maria Rossolini – Careggi University Hospital and Claudio Macchi – Don Gnocchi Foundation
White Paper: Supporting CDC’s Four Core Actions to Fight Antimicrobial Resistance
CDC has declared the complex problem of AMR a serious threat today, which will result in potential catastrophic consequences with continued inaction. To combat AMR, the CDC has identified 4 core actions, all of which can be addressed through rapid molecular diagnostics:
Confronting CRE: The Rise of Superbugs and the Role of Diagnostics in Controlling Their Spread